肠道菌群
肠-脑轴
自闭症谱系障碍
微生物群
自闭症
肠道微生物群
医学
生物信息学
神经科学
生物
免疫学
精神科
作者
Cinara L. Gonçalves,Tejaswini Doifode,Victória Linden de Rezende,Maiara de Aguiar da Costa,J. Marc Rhoads,César Soutullo
出处
期刊:Life Sciences
[Elsevier]
日期:2023-12-19
卷期号:337: 122357-122357
被引量:9
标识
DOI:10.1016/j.lfs.2023.122357
摘要
The gut-brain axis is gaining more attention in neurodevelopmental disorders, especially autism spectrum disorder (ASD). Many factors can influence microbiota in early life, including host genetics and perinatal events (infections, mode of birth/delivery, medications, nutritional supply, and environmental stressors). The gut microbiome can influence blood-brain barrier (BBB) permeability, drug bioavailability, and social behaviors. Developing microbiota-based interventions such as probiotics, gastrointestinal (GI) microbiota transplantation, or metabolite supplementation may offer an exciting approach to treating ASD. This review highlights that RNA sequencing, metabolomics, and transcriptomics data are needed to understand how microbial modulators can influence ASD pathophysiology. Due to the substantial clinical heterogeneity of ASD, medical caretakers may be unlikely to develop a broad and effective general gut microbiota modulator. However, dietary modulation followed by administration of microbiota modulators is a promising option for treating ASD-related behavioral and gastrointestinal symptoms. Future work should focus on the accuracy of biomarker tests and developing specific psychobiotic agents tailored towards the gut microbiota seen in ASD patients, which may include developing individualized treatment options.
科研通智能强力驱动
Strongly Powered by AbleSci AI